Skip to main content
. 2021 Aug 10;13(8):e17046. doi: 10.7759/cureus.17046

Table 1. Studies comparing denosumab vs zoledronic acid.

RCT: randomized control trial; SRE: skeletal-related events

Column 1 Column 2 Column 3
Type of study Author Results
RCT Lipton et al. Delay in first SRE (HR 0.82, CI 0.71-0.95,p =0.01), median time: unknown in denosumab vs 26.4 months in zoledronic acid [7].
RCT Fizazi et al. Delay in first SRE (HR 0.82, CI 0.71-0.95, p<=0.01), median time: 20.7 months in denosumab vs 17.1 months in zoledronic acid [8].
meta-analysis Chen C et al. Delay in first SRE (HR = 0.86; 95% CI, 0.80–0.93; P = 0.0001), no difference in overall survival [9].
meta-analysis Zheng G et al. Delay in first SRE (OR =0.82; 95% CI, 0.75-0.89; P < 0.01), no difference in overall survival [10].
meta-analysis Hayes et al. Delay onset of bone metastasis in non-metastatic prostate cancer (RR 0.83, CI 0.73-0.95; P <0.01) [11].